Related Experiment Video
Updated: Jun 16, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Reducing glycemic variability in intensive care unit patients: a new therapeutic target?
Moritoki Egi1, Rinaldo Bellomo
1Department of Anesthesiology and Resuscitology, Okayama University Hospital, Shikata, Okayama, Japan. moriori@tg8.so-net.ne.jp
Abstract:
Acute hyperglycemia is common in critically ill patients. Strict control of blood glucose (BG) concentration has been considered important because hyperglycemia is associated independently with increased intensive care unit mortality. After intensive insulin therapy was reported to reduce mortality in selected surgical critically ill patients, lowering of BG levels was recommended as a means of improving patient outcomes. However, a large multicenter multination study has found that intensive insulin therapy increased mortality significantly. A difference in variability of BG control may be one possible explanation why the effect of intensive insulin therapy varied from beneficial to harmful. Several studies have confirmed significant associations between variability of BG levels and patient outcomes. Decreasing the variability of the BG concentration may be an important dimension of glucose management. If reducing swings in the BG concentration is a major biologic mechanism behind the putative benefits of glucose control, it may not be necessary to pursue lower glucose levels with their attendant risk of hypoglycemia.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Hypoglycemia and Glucagon
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetic Ketoacidosis l: Introduction
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Glinides